HKMP.F Stock Overview Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Hikma Pharmaceuticals PLC Competitors Price History & Performance
Summary of share price highs, lows and changes for Hikma Pharmaceuticals Historical stock prices Current Share Price UK£26.64 52 Week High UK£26.64 52 Week Low UK£22.33 Beta 0.42 1 Month Change 6.47% 3 Month Change n/a 1 Year Change 10.26% 3 Year Change -2.60% 5 Year Change 15.83% Change since IPO 252.85%
Recent News & Updates
Hikma Pharmaceuticals PLC to Report Fiscal Year 2024 Results on Feb 26, 2025 Dec 25
Hikma Pharmaceuticals plc Announces the Shelf-Life Extension of KLOXXADO Nasal Spray 8mg from 24 to 36 Months Aug 16 Hikma Pharmaceuticals PLC Revises Group Earnings Guidance for the Full Year of 2024 Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024
Hikma Pharmaceuticals PLC Announces Executive Changes Apr 16
Hikma Pharmaceuticals PLC, Annual General Meeting, Apr 25, 2024 Feb 22 See more updates
Hikma Pharmaceuticals PLC to Report Fiscal Year 2024 Results on Feb 26, 2025 Dec 25
Hikma Pharmaceuticals plc Announces the Shelf-Life Extension of KLOXXADO Nasal Spray 8mg from 24 to 36 Months Aug 16 Hikma Pharmaceuticals PLC Revises Group Earnings Guidance for the Full Year of 2024 Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024
Hikma Pharmaceuticals PLC Announces Executive Changes Apr 16
Hikma Pharmaceuticals PLC, Annual General Meeting, Apr 25, 2024 Feb 22
Hikma Announces US Launch of COMBOGESIC IV Feb 05
Hikma Pharmaceuticals PLC Announces Company Secretary Change Dec 29 Hikma Pharmaceuticals PLC to Report First Half, 2024 Results on Aug 08, 2024
Hikma Pharmaceuticals PLC Provides Earnings Guidance for the Year 2023 Nov 02 Hikma Pharmaceuticals PLC(LSE:HIK) dropped from FTSE 250 Index
Hikma Pharmaceuticals PLC Appoints Bill Larkins as President of Its Injectables Business, Effective 1 September 2023 Aug 09
Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation Jul 30
Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation Jul 29
Hikma Exceeds 150 Injectable Medicines in the US with Launch of Dobutamine Injection, USP Jun 16
Hikma Launches Authorized Generic of Xyrem® (Sodium Oxybate) in the US Jan 04
Hikma Pharmaceuticals PLC to Report Fiscal Year 2022 Results on Feb 23, 2023 Nov 11
Hikma Pharmaceuticals PLC Appoints Deneen Vojta as Director Oct 14
Hikma Pharmaceuticals PLC Announces Board Appointments Sep 30
Hikma Pharmaceuticals PLC(LSE:HIK) dropped from FTSE 100 Index Sep 19
Hikma Pharmaceuticals PLC and Glenmark Specialty S.A., Launches RYALTRIS in US Aug 31
Hikma Pharmaceuticals plc Recommends Interim Dividend, Payable on 19 September 2022 Aug 04
Hikma Pharmaceuticals plc Announces Company Secretary Change Jun 16
Hikma Pharmaceuticals PLC Announces Chief Executive Officer Changes May 24
Hikma Pharmaceuticals PLC Approves Final Dividend for the Year 2021 May 02
Hikma Pharmaceuticals PLC (LSE:HIK) completed the acquisition of Custopharm Inc. from Water Street Healthcare Partners, LLC. Apr 22 Hikma Pharmaceuticals PLC (LSE:HIK) announces an Equity Buyback for £300 million worth of its shares. Hikma Pharmaceuticals PLC Provides Revenue Guidance for 2022
Hikma Pharmaceuticals PLC (LSE:HIK) completed the acquisition of Canadian assets of Teligent Inc from Teligent, Inc. (OTCPK:TLGT.Q). Feb 04
Hikma Pharmaceuticals PLC (LSE:HIK) agreed to acquire Canadian assets of Teligent Inc. from Teligent, Inc. (OTCPK:TLGT.Q) for $45.7 million. Jan 18
Hikma Pharmaceuticals PLC (LSE:HIK) agreed to acquire Custopharm Inc. from Water Street Healthcare Partners, LLC for approximately $430 million. Sep 29
Hikma Pharmaceuticals PLC Announces US FDA Approval of KLOXXADO Apr 30
Hikma Pharmaceuticals PLC, Annual General Meeting, Apr 23, 2021 Feb 25
Eyevance Pharmaceuticals Expands U.S. Promotion of ZERVIATE® In Agreement with Hikma Feb 16
Hikma Pharmaceuticals PLC to Report Fiscal Year 2020 Results on Feb 25, 2021 Feb 08 Hikma Pharmaceuticals PLC (LSE:HIK) entered into a non-binding term sheet to acquire 91.2% stake in GlaxoSmithKline S.A.E (CASE:BIOC) from Glaxo Group Limited.
Hikma Pharmaceuticals PLC Provides Update on Generic Advair Diskus® Jan 17
Hikma Pharmaceuticals PLC Launches Generic Advair Diskus® Dec 19 Amarin Corporation plc Files Patent Infringement Lawsuit Against Hikma Pharmaceuticals PLC and Hikma’s U.S. affiliate
Hikma Pharmaceuticals PLC Launches Icosapent Ethyl Capsules 1gm in the US Nov 07 Hikma Pharmaceuticals plc Announces Board and Committee Changes
Hikma Pharmaceuticals PLC and Arecor Limited Expand Collaboration with New Agreement to Develop and Commercialize Ready-To-Administer Medicine Oct 20
Hikma Pharmaceuticals PLC Updates on ANDA for Generic Advair Diskus Sep 23
Hikma Pharmaceuticals PLC to Report November,2020 Results on Nov 05, 2020 Sep 17 Shareholder Returns HKMP.F US Pharmaceuticals US Market 7D 0% 2.3% -0.9% 1Y 10.3% 4.3% 22.6%
See full shareholder returns
Return vs Market: HKMP.F underperformed the US Market which returned 22.6% over the past year.
Price Volatility Is HKMP.F's price volatile compared to industry and market? HKMP.F volatility HKMP.F Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 10.4% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.7% 10% least volatile stocks in US Market 3.2%
Stable Share Price: HKMP.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine HKMP.F's volatility change over the past year.
About the Company Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Show more Hikma Pharmaceuticals PLC Fundamentals Summary How do Hikma Pharmaceuticals's earnings and revenue compare to its market cap? HKMP.F fundamental statistics Market cap US$6.30b Earnings (TTM ) US$285.00m Revenue (TTM ) US$3.02b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) HKMP.F income statement (TTM ) Revenue US$3.02b Cost of Revenue US$1.57b Gross Profit US$1.45b Other Expenses US$1.16b Earnings US$285.00m
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 26, 2025
Earnings per share (EPS) 1.29 Gross Margin 47.99% Net Profit Margin 9.45% Debt/Equity Ratio 53.2%
How did HKMP.F perform over the long term?
See historical performance and comparison Dividends
2.8% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/01 03:40 End of Day Share Price 2025/01/24 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Hikma Pharmaceuticals PLC is covered by 37 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kamla Singh AlphaValue Simon Mather Barclays Emily Field Barclays
Show 34 more analysts 
